Based on the positive clinical results documented in the outcome data (recently published in The Lancet Diabetes & Endocrinology) of a major international randomized controlled trial of our LeucoPatch® wound healing technology, Reapplix’s primary focus now shifts from development to commercialization.

As part of our commercialization strategy, our new global brand name for LeucoPatch® will be 3C Patch®. During 2019, we will transition to this new brand name, which derives from the 3 step process involved in creating a 3 layered patch (Centrifugation, Coagulation, Compaction) and provides a generic and internationally recognizable brand.

The marketing of 3C Patch®, to which Reapplix holds the patents and the global rights, has begun in Denmark.